Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

EBAG9 controls CD8+ T cell memory formation responding to tumor challenge in mice.

Tytuł:
EBAG9 controls CD8+ T cell memory formation responding to tumor challenge in mice.
Autorzy:
Rehm A; Department of Translational Tumorimmunology, Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Wirges A; Department of Translational Tumorimmunology, Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Hoser D; Institute of Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.; German Cancer Research Center, Heidelberg, Germany.; German Cancer Consortium, Berlin, Germany.
Fischer C; Genomics Platform, Scientific Infrastructure Department, and.
Herda S; Department of Translational Tumorimmunology, Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Gerlach K; Department of Translational Tumorimmunology, Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Sauer S; Genomics Platform, Scientific Infrastructure Department, and.
Willimsky G; Institute of Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.; German Cancer Research Center, Heidelberg, Germany.; German Cancer Consortium, Berlin, Germany.
Höpken UE; Department of Microenvironmental Regulation in Autoimmunity and Cancer, Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Źródło:
JCI insight [JCI Insight] 2022 Jun 08; Vol. 7 (11). Date of Electronic Publication: 2022 Jun 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: Ann Arbor, Michigan : American Society for Clinical Investigation, [2016]-
MeSH Terms:
CD8-Positive T-Lymphocytes*
Neoplasms*
Adoptive Transfer ; Animals ; Mice ; Minor Histocompatibility Antigens
References:
Blood. 2013 Feb 28;121(9):1612-21. (PMID: 23247726)
J Exp Med. 2008 Aug 4;205(8):1859-68. (PMID: 18625745)
Immunity. 2016 Aug 16;45(2):389-401. (PMID: 27521269)
Immunol Rev. 2010 May;235(1):206-18. (PMID: 20536565)
Semin Immunopathol. 2015 May;37(3):301-10. (PMID: 25860798)
Immunology. 2013 Jul;139(3):277-84. (PMID: 23347146)
Oncogene. 1999 Nov 22;18(49):6910-24. (PMID: 10602466)
Nat Rev Immunol. 2015 Sep 15;15(9):574-84. (PMID: 26272293)
Nat Rev Immunol. 2008 Feb;8(2):107-19. (PMID: 18219309)
Oncogenesis. 2014 Nov 03;3:e126. (PMID: 25365482)
Cell Death Differ. 2005 Nov;12(11):1398-406. (PMID: 15920533)
Blood. 2005 Jun 15;105(12):4871-7. (PMID: 15713793)
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6955-60. (PMID: 12011454)
Annu Rev Immunol. 2019 Apr 26;37:457-495. (PMID: 30676822)
Cancer Discov. 2014 Dec;4(12):1448-65. (PMID: 25252690)
Nat Biotechnol. 2020 Dec;38(12):1408-1414. (PMID: 32747759)
Nucleic Acids Res. 2002 Jan 1;30(1):207-10. (PMID: 11752295)
J Exp Med. 2014 Jan 13;211(1):105-20. (PMID: 24367005)
J Immunol. 2001 Oct 1;167(7):3756-64. (PMID: 11564792)
Nat Immunol. 2013 Apr;14(4):404-12. (PMID: 23396170)
J Immunol Methods. 1986 Nov 6;93(2):157-65. (PMID: 3490518)
Nat Immunol. 2011 Nov 06;12(12):1221-9. (PMID: 22057289)
Nature. 2009 Mar 12;458(7235):211-4. (PMID: 19182777)
Curr Opin Immunol. 2002 Jun;14(3):360-5. (PMID: 11973135)
Nat Immunol. 2011 Nov 06;12(12):1230-7. (PMID: 22057288)
Blood. 2015 Jul 9;126(2):203-11. (PMID: 25800048)
Immunity. 2007 Aug;27(2):281-95. (PMID: 17723218)
J Exp Med. 1997 May 19;185(10):1777-83. (PMID: 9151703)
Immunity. 2013 Aug 22;39(2):347-56. (PMID: 23932571)
Nat Rev Immunol. 2015 Jun;15(6):388-400. (PMID: 25998963)
Nat Rev Immunol. 2012 Nov;12(11):749-61. (PMID: 23080391)
J Exp Med. 2008 Jul 7;205(7):1687-700. (PMID: 18573907)
J Exp Med. 2018 Apr 2;215(4):1153-1168. (PMID: 29449309)
Annu Rev Immunol. 2002;20:323-70. (PMID: 11861606)
Immunity. 2011 Nov 23;35(5):792-805. (PMID: 22118527)
Nat Immunol. 2003 Dec;4(12):1191-8. (PMID: 14625547)
Nat Biotechnol. 2018 Jun;36(5):411-420. (PMID: 29608179)
Cell Syst. 2015 Dec 23;1(6):417-425. (PMID: 26771021)
Immunity. 2010 Jan 29;32(1):79-90. (PMID: 20096607)
Cancer Control. 2002 Mar-Apr;9(2):114-22. (PMID: 11965232)
Nat Commun. 2014 Sep 30;5:5057. (PMID: 25266931)
Nat Rev Immunol. 2003 Apr;3(4):269-79. (PMID: 12669018)
Nat Rev Immunol. 2009 Sep;9(9):662-8. (PMID: 19680250)
Nat Immunol. 2005 Aug;6(8):793-9. (PMID: 16025119)
Nat Rev Immunol. 2002 Apr;2(4):251-62. (PMID: 12001996)
Blood. 2015 Jul 9;126(2):212-21. (PMID: 25979947)
Nat Immunol. 2000 Nov;1(5):433-40. (PMID: 11062504)
J Clin Invest. 2009 Aug;119(8):2184-203. (PMID: 19620783)
Nat Immunol. 2002 Sep;3(9):844-51. (PMID: 12172545)
Immunol Rev. 2007 Dec;220:102-12. (PMID: 17979842)
J Clin Invest. 2008 Jul;118(7):2427-37. (PMID: 18551193)
Contributed Indexing:
Keywords: Adaptive immunity; Immunology; Leukemias; Oncology; T cells
Substance Nomenclature:
0 (Minor Histocompatibility Antigens)
Entry Date(s):
Date Created: 20220428 Date Completed: 20220609 Latest Revision: 20220716
Update Code:
20240104
PubMed Central ID:
PMC9220939
DOI:
10.1172/jci.insight.155534
PMID:
35482418
Czasopismo naukowe
Insight into processes that determine CD8+ T cell memory formation has been obtained from infection models. These models are biased toward an inflammatory milieu and often use high-avidity CD8+ T cells in adoptive-transfer procedures. It is unclear whether these conditions mimic the differentiation processes of an endogenous repertoire that proceed upon noninflammatory conditions prevailing in premalignant tumor lesions. We examined the role of cytolytic capacity on CD8+ T cell fate decisions when primed by tumor cells or by minor histocompatibility antigen-mismatched leukocytes. CD8+ memory commitment was analyzed in Ebag9-deficient mice that exhibited enhanced tumor cell lysis. This property endowed Ebag9-/- mice with extended control of Tcl-1 oncogene-induced chronic lymphocytic leukemia progression. In Ebag9-/- mice, an expanded memory population was obtained for anti-HY and anti-SV-40 T antigen-specific T cells, despite unchanged effector frequencies in the primary response. By comparing the single-cell transcriptomes of CD8+ T cells responding to tumor cell vaccination, we found differential distribution of subpopulations between Ebag9+/+ and Ebag9-/- T cells. In Ebag9-/- cells, these larger clusters contained genes encoding transcription factors regulating memory cell differentiation and anti-apoptotic gene functions. Our findings link EBAG9-controlled cytolytic activity and the commitment to the CD8+ memory lineage.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies